AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ginkgo Bioworks Surges 18.9%, Can Further Upside Be Expected?
ByAinvest
Tuesday, Jul 1, 2025 8:05 am ET1min read
Ginkgo Bioworks Holdings (DNA) shares surged 18.9% to $11.25, driven by positive investor expectations for its proprietary cell programming platforms, Foundry and Codebase. The company is expected to post a quarterly loss of $1.44 per share and revenues of $43 million. The consensus EPS estimate has been revised 12.1% lower over the last 30 days. DNA carries a Zacks Rank #2 (Buy) and is part of the Medical - Biomedical and Genetics industry.
Ginkgo Bioworks Holdings, Inc. (DNA) experienced a significant 18.9% increase in its stock price, reaching $11.25 on Monday, June 19, 2025. The surge was driven by positive investor expectations for the company's proprietary cell programming platforms, Foundry and Codebase. Analysts anticipate that Ginkgo Bioworks will report a quarterly loss of $1.44 per share and revenues of $43 million [1].The consensus EPS estimate has been revised 12.1% lower over the last 30 days, indicating a shift in analyst sentiment. Despite this, DNA carries a Zacks Rank #2 (Buy) and is part of the Medical - Biomedical and Genetics industry, which ranks in the top 34% of all industries [2].
Institutional investors have also shown interest in Ginkgo Bioworks. During the fourth quarter, SBI Securities Co. Ltd. bought a new stake worth approximately $29,000, while US Bancorp DE grew its stake by 43.5% in the first quarter. KLP Kapitalforvaltning AS and CWM LLC also increased their stakes in the company [1].
Ginkgo Bioworks, headquartered in the United States, develops a platform for cell programming. Its platform is used to program cells to enable biological production of products such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves a variety of industries, including pharmaceuticals, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense [1].
References:
[1] https://www.marketbeat.com/instant-alerts/ginkgo-bioworks-nysedna-shares-up-134-still-a-buy-2025-06-30/
[2] https://www.nasdaq.com/articles/ginkgo-bioworks-holdings-inc-dna-stock-moves-141-what-you-should-know
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet